James McNulty

James McNulty

Director of Finance/CFO at HEDGEPATH PHARMACEUTICALS INC

Net worth: 176 646 $ as of 2026-08-30

76 year
Health Technology
Commercial Services
Distribution Services

Profile

James A. McNulty is the founder of Pender, McNulty & Newkirk, founded in 1976.
Mr. McNulty is also the founder of McNulty & Co.,McNulty, Garcia & Ortiz PA..
Mr. McNulty is Director-Tampa Bay Chapter at Financial Executives International since 2013.
Mr. McNulty is Independent Director at Lunai Bioworks, Inc. starting 2024.
Mr. McNulty is a Member of The American Institute of Certified Public Accountants.
Mr. McNulty is a Member of Florida Institute of Certified Public Accountants.
Mr. McNulty is Chief Financial Officer, Secretary & Treasurer at Inhibitor Therapeutics, Inc. since 2022.
Mr. McNulty is Chief Financial Officer at Repurposed Therapeutics, Inc. Mr. McNulty is Chief Financial Officer at MIRALOGX LLC.
Former positions include Chief Executive Officer at MyMD Pharmaceuticals (Florida), Inc. from 2014 to 2020.
Lead Independent Director at CV Sciences, Inc. from 2016 to 2020.
Director at Quantum Technology Sciences, Inc. Chief Financial Officer at Rock Creek Pharmaceuticals, Inc. from 1998 to 2000.
Treasurer & Senior Vice President at BioDelivery Sciences International, Inc. from 2013 to 2014.
Chief Financial Officer at CeleXx Corp.
Chief Financial Officer at BioVest International, Inc. from 2003 to 2007.
Secretary & Treasurer at Accentia Biopharmaceuticals, Inc. from 2009 to 2013.
Chief Operating & Financial Officer at American Prescription Providers, Inc. from 2000 to 2002.
Chief Financial Officer at TEAMM Pharmaceuticals, Inc. Chief Financial Officer at RetinaPharma Technologies, Inc. Chief Financial Officer at Hopkins Capital Group.
Chief Financial Officer at Telomir Pharmaceuticals, Inc. Chief Executive & Financial Officer at Defender Pharmaceuticals, Inc. Chief Financial Officer at MIRA Pharmaceuticals, Inc. from 2020 to 2023.
Education includes undergraduate degree from the University of South Florida, conferred in 1972.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-08-16 1,946,135 ( 1.12% ) 173 206 $ 2026-08-30
2026-04-09 1,512 ( 0.03% ) 3 440 $ 2026-08-30

James McNulty active positions

CompaniesPositionStart
HEDGEPATH PHARMACEUTICALS INC Director of Finance/CFO 2022-12-12
LUNAI BIOWORKS INC. Director/Board Member 2024-10-13
Repurposed Therapeutics, Inc.
Director of Finance/CFO -
Corporate Officer/Principal -
Corporate Officer/Principal -
Corporate Officer/Principal -

Former positions of James McNulty

CompaniesPositionEnd
TELOMIR PHARMACEUTICALS, INC. Director of Finance/CFO 2023-12-31
MIRA PHARMACEUTICALS, INC. Director of Finance/CFO 2023-03-31
CV SCIENCES, INC. Director/Board Member 2020-07-26
░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░ ░░ ░░░░░░░░░░░ ░░░░░░░░░░
See the detail of James McNulty's experience

Training of James McNulty

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

56

1st degree connections

25

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies25

Health Technology

Health Technology

Technology Services

Health Technology

Health Technology

Health Technology

Health Technology

Retail Trade

Commercial Services

Distribution Services

Consumer Services

Commercial Services

Distribution Services

Pender, McNulty & Newkirk

Commercial Services

McNulty, Garcia & Ortiz PA

Electronic Technology

Finance

Health Technology

Repurposed Therapeutics, Inc.

Health Technology

Health Technology

Health Technology

Health Technology

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!